Clinical Trial Update: Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating an angiotensin-converting enzyme inhibitor for treating IgA nephropathy, a form of glomerulonephritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Iga Nephropathy

Drugs mentioned

• ACE inhibitor (angiotensin-converting enzyme inhibitor)

Snippet

Sponsor: Sanofi | Conditions: Glomerulonephritis | Phase 3 | Status: COMPLETED